ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The following table provides a reconciliation of cash and cash equivalents reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows.


(in thousands)	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	15,402	$	21,837
Total cash and cash equivalents shown in the statements of cash flows	$	15,402	$	21,837

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other liabilities consist of the following:


(in thousands)	March 31, 2023		December 31, 2022
Accrued payroll	$	666	$	264
Accrued patient treatment costs	887		675
Accrued clinical research costs	994		841
Accrued manufacturing costs	345		434
Accrued professional services	305		207
Accrued other	58		56
Total accrued expenses and other current liabilities	$	3,255	$	2,477

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following outstanding shares of common stock equivalents were excluded from the computations of diluted loss per share of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.


	March 31, 2023	March 31, 2022
Anti-dilutive common stock equivalents:	Number of Shares
Redeemable convertible series 1 preferred stock	4,520,000	4,520,000
Warrants to purchase common stock	5,750,000	5,750,000
Options to purchase common stock	3,289,480	2,064,537
Unvested shares of restricted stock units	618,620	10,500
Total anti-dilutive common stock equivalents	14,178,100	12,345,037